Swedencare AB ("Swedencare") provides the following trading update for the fourth quarter of 2025. Sales continue to grow organically at double‑digit levels and above market growth, while profitability came in lower than expected mainly due to extraordinary marketing and sales efforts, primarily linked to supporting launches with our newest large retail partners and acquired Amazon account.
Preliminary net revenue for the fourth quarter amounted to 682 MSEK, corresponding to 11% organic growth. For the full year 2025, net revenue amounted to 2 683 MSEK, corresponding to an organic growth of 9%.
The main one‑off items impacting the profitability in the quarter were:
As a result, preliminary operational EBITDA margin amounts to 15-16% for the quarter. For the full year an operational EBITDA margin of 19% is expected.
CEO Statement
“Swedencare should continuously deliver double‑digit growth combined with strong profitability, which makes me disappointed with the profitability outcome this quarter. It is important to highlight, however, that several of our companies and brands delivered a strong Q4, both in growth and profitability.
During the past two years we have focused on laying the groundwork for stronger future performance. In 2026, we will have completed the Amazon transition for NaturVet and Europe, giving us full control of marketing and pricing. We will also expand our collaborations in the veterinary sector in both Europe and North America, launch several clinically proven products across multiple brands, significantly grow our CDMO business within Pharma, and normalize margins within our Big Box channel.
Overall, our presence in the Big Box segment strengthens Swedencare’s long‑term growth profile and represents a key building block in achieving our updated financial targets. Worth noting is that we have almost doubled our Walmart out-the-door sales in January showing that our display investment has had an immediate impact.”
– Håkan Lagerberg, CEO, Swedencare